[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20084968L - Dihydropyrazolpyrimidinonderivater - Google Patents

Dihydropyrazolpyrimidinonderivater

Info

Publication number
NO20084968L
NO20084968L NO20084968A NO20084968A NO20084968L NO 20084968 L NO20084968 L NO 20084968L NO 20084968 A NO20084968 A NO 20084968A NO 20084968 A NO20084968 A NO 20084968A NO 20084968 L NO20084968 L NO 20084968L
Authority
NO
Norway
Prior art keywords
group
alkyl group
aal
pyridyl
cancer
Prior art date
Application number
NO20084968A
Other languages
Norwegian (no)
Other versions
NO341617B1 (en
Inventor
Takeshi Sagara
Makoto Bamba
Keiji Takahashi
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Hidetomo Furuyama
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084968(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20084968L publication Critical patent/NO20084968L/en
Publication of NO341617B1 publication Critical patent/NO341617B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

hvor A1 er valgt fra den følgende formel (aal): (aa1), Ri er en lavere alkenylgruppe eller en lavere alkynylgruppe, R2 er en fenyl-, pyridyl- eller tienyl-gruppe, og R5 og R6 er et hydrogenatom, en lavere alkylgruppe eller en hydroksy-lavere-alkylgruppe, osv. Forbindelsene oppviser utmerket Weel-kinase-inhiberende virkning og er derfor anvendelige innenfor det medisinske området, spesielt for behandling av forskjellige typer kreft.wherein A1 is selected from the following formula (aal): (aa1), R 1 is a lower alkenyl group or a lower alkynyl group, R 2 is a phenyl, pyridyl or thienyl group, and R 5 and R 6 are a hydrogen atom, a lower alkyl group or a hydroxy-lower-alkyl group, etc. The compounds exhibit excellent Weel kinase inhibitory activity and are therefore useful in the medical field, especially for the treatment of various types of cancer.

NO20084968A 2006-04-27 2008-11-26 Dihydropyrazole pyrimidinone derivatives, their use in therapy and in the treatment of cancer, their use in the manufacture of a medicament, and in use as a radiation sensitizer, their pharmaceutical composition, and a combined preparation for administration in the treatment of cancer. NO341617B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059408 WO2007126122A1 (en) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinone derivatives

Publications (2)

Publication Number Publication Date
NO20084968L true NO20084968L (en) 2008-11-26
NO341617B1 NO341617B1 (en) 2017-12-11

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084968A NO341617B1 (en) 2006-04-27 2008-11-26 Dihydropyrazole pyrimidinone derivatives, their use in therapy and in the treatment of cancer, their use in the manufacture of a medicament, and in use as a radiation sensitizer, their pharmaceutical composition, and a combined preparation for administration in the treatment of cancer.

Country Status (39)

Country Link
US (4) US7935708B2 (en)
EP (2) EP2017278B1 (en)
JP (2) JP4513919B2 (en)
KR (1) KR101409161B1 (en)
CN (1) CN101432284B (en)
AR (1) AR060635A1 (en)
AT (1) ATE475662T1 (en)
AU (1) AU2007244185B2 (en)
BR (1) BRPI0710081A2 (en)
CA (1) CA2650119C (en)
CR (1) CR10359A (en)
CY (2) CY1111069T1 (en)
DE (1) DE602007008085D1 (en)
DK (2) DK2016080T3 (en)
DO (1) DOP2007000084A (en)
EC (1) ECSP088812A (en)
ES (2) ES2609087T3 (en)
GT (1) GT200800211A (en)
HK (1) HK1132498A1 (en)
HN (1) HN2008001532A (en)
HR (2) HRP20100563T1 (en)
HU (1) HUE032987T2 (en)
IL (1) IL194367A (en)
LT (1) LT2017278T (en)
MA (1) MA30428B1 (en)
MX (1) MX2008013063A (en)
MY (1) MY145408A (en)
NO (1) NO341617B1 (en)
NZ (1) NZ571196A (en)
PE (1) PE20080695A1 (en)
PL (2) PL2016080T3 (en)
PT (2) PT2017278T (en)
RU (1) RU2437885C2 (en)
SI (2) SI2017278T1 (en)
SV (1) SV2009003060A (en)
TW (1) TWI409262B (en)
UA (1) UA96152C2 (en)
WO (2) WO2007126122A1 (en)
ZA (1) ZA200807748B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (en) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd DERIVATIVES OF 1,2-DIHIDRO-3H-PIRAZOLO [3,4-D] PIRIMIDIN-3-ONA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF CANCER
WO2008133866A1 (en) * 2007-04-25 2008-11-06 Merck & Co., Inc. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
AU2008315048A1 (en) * 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
ES2430053T3 (en) * 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedure to produce bicycloaniline derivatives
WO2010067888A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP2012518598A (en) * 2009-02-25 2012-08-16 Ｍｓｄ株式会社 Pyrimidopyrimidoindazole derivatives
EP2473633A4 (en) * 2009-09-02 2013-03-06 Msd Kk USE OF BIOMARKER (S) TO IDENTIFY A PATIENT RESPONDING TO WEE1 INHIBITOR AND METHODS OF TREATING DYSFUNCTIONAL OR ADHERENT P53-MEDIATED CANCER BY ADMINISTERING A WEE1 INHIBITOR
EP2477628B1 (en) 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
ES2621857T3 (en) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combination of control point kinase 1 inhibitors and WEE1 kinase inhibitors
KR102093947B1 (en) * 2011-04-27 2020-03-26 제온 코포레이션 Polymerizable compound, polymerizable composition, polymer, and optically anisotropic material
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
EP2776434A1 (en) * 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
WO2014168941A1 (en) 2013-04-09 2014-10-16 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
RU2689557C2 (en) * 2014-12-17 2019-05-28 Дельта-Флай Фарма, Инк. Using pharmaceutical composition for treating or creating remission conditions in elderly patient with solid cancer
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
AR104293A1 (en) 2015-04-17 2017-07-12 Abbvie Inc INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING
UY36629A (en) 2015-04-17 2016-11-30 Abbvie Inc INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING
PT3345907T (en) * 2015-09-01 2020-06-23 Taiho Pharmaceutical Co Ltd Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
CN105130986B (en) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 Pyrimidine or pyridopyridine ketone compounds and its application
US10947238B2 (en) * 2015-11-01 2021-03-16 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
CN106271589B (en) * 2016-06-23 2018-12-28 中山市美捷时包装制品有限公司 It is a kind of for pre-installing the assembling equipment of valve rod, spring, gasket
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
JP6733050B2 (en) 2016-09-15 2020-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heteroaryl carboxamide compounds as inhibitors of RIPK2
CN106719769A (en) * 2016-11-28 2017-05-31 山东农业大学 A kind of disease pest containing lentinan, Difenoconazole and thiacloprid is simultaneous to control composition pesticide
ES2970913T3 (en) 2016-12-08 2024-05-31 Lixte Biotechnology Inc Oxabicycloheptanes for modulation of the immune response
ES2902050T3 (en) * 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one derivative as Wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
EP3604306B1 (en) * 2017-03-23 2022-10-26 Shanghai de Novo Pharmatech Co., Ltd. Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
MX2019011506A (en) 2017-03-31 2019-11-01 Seattle Genetics Inc Combinations of chk1- and wee1 - inhibitors.
BR112020002104A2 (en) * 2017-08-01 2020-08-04 Recurium Ip Holdings, Llc 1,2-dihydro-3h-pyrazolo [3,4-d] pyrimidin-3-one analogs
CN109422754A (en) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 Pyrazolo [3,4-d] pyrimidine -3- ketone derivatives, its pharmaceutical composition and application
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc Heterocyclic compounds and uses thereof
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
PT3712150T (en) 2017-11-01 2024-08-22 Wuxi Biocity Biopharmaceutics Co Ltd Macrocyclic compound serving as wee1 inhibitor and applications thereof
CN109810111B (en) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 Pyrazolopyrimidine compound, and preparation method and application thereof
CN111315747B (en) * 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 Dihydropyrazolopyrimidine compound and preparation method and application thereof
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
US12220415B2 (en) 2018-02-28 2025-02-11 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN108653282B (en) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 Application of benzothiazoles and benzopyrroles in the preparation of antitumor drugs
CN112955454A (en) * 2018-10-26 2021-06-11 石家庄智康弘仁新药开发有限公司 Pyrimido pyrazolone derivative as Wee1 inhibitor and application thereof
CN111662283B (en) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 Imidazopyridine compound and intermediate, preparation method and application thereof
CN113614087B (en) * 2019-03-22 2023-06-02 首药控股(北京)股份有限公司 WEE1 inhibitor and preparation and application thereof
EP3952875A4 (en) * 2019-04-09 2022-12-28 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
SG11202110615TA (en) 2019-04-09 2021-10-28 Nuvation Bio Inc Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
HRP20241008T1 (en) 2019-04-30 2024-11-08 Wuxi Biocity Biopharmaceutics Co., Ltd. CRYSTAL FORM OF WEE1 INHIBITOR COMPOUND AND ITS USE
CN112142748B (en) 2019-06-28 2023-07-04 上海医药集团股份有限公司 Pyrazolopyrimidine compound, and preparation method and application thereof
EP3992193A4 (en) 2019-06-28 2023-08-16 Shanghai Pharmaceuticals Holding Co., Ltd. Pyrazolopyrimidine compound, preparation method for same, and applications thereof
MX2022004934A (en) 2019-10-25 2022-05-16 Astrazeneca Ab Methods of treating cancer.
AU2020407573A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
CN113387962A (en) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof
CN115698006B (en) 2020-06-17 2024-03-29 微境生物医药科技(上海)有限公司 Pyrazolo [3,4-d ] pyrimidin-3-one derivatives as Wee-1 inhibitors
KR102549484B1 (en) * 2020-12-08 2023-06-29 한국화학연구원 Pyrazolopyrimidine sulfonamide derivatives and pharmaceutical composition for prevention or treatment of cancer-related disease containing the same as an active ingredient
CN116848118A (en) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 Pyrazolo [3,4-d ] pyrimidin-3-one derivatives as Wee-1 inhibitors
CN116867787A (en) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 Pyrazolo [3,4-d ] pyrimidin-3-one derivatives
WO2022171126A1 (en) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 Fused ring compound used as wee-1 inhibitor
CN115197221B (en) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 Dihydropyrazolopyrimidinone macrocyclic derivatives and their use
US20240252655A1 (en) 2021-04-29 2024-08-01 Novartis Ag Deubiquitinase-targeting chimeras and related methods
CN117222648A (en) 2021-04-30 2023-12-12 微境生物医药科技(上海)有限公司 Fused ring compounds as Wee-1 inhibitors, process for their preparation and their use
CA3211181A1 (en) 2021-05-28 2022-12-01 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Wee1 inhibitor and use thereof
TW202328142A (en) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 Pyrimidino-dihydropyrazolone-containing derivative, pharmaceutically acceptable salt thereof, preparation method and application of pyrimidino-dihydropyrazolone-containing derivative
CN113735863A (en) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Preparation process of Wee1 inhibitor avaposertib
CN113880844B (en) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Chemical synthesis method of Wee1 protein kinase inhibitor avaposertib
WO2023072301A1 (en) * 2021-11-01 2023-05-04 正大天晴药业集团股份有限公司 Pyrazolo[3,4-d]pyrimidin-3-one compound and medical use thereof
CN116462687B (en) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 WEE1 inhibitors and their preparation and use
CN116836184A (en) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Preparation and application of Wee1 kinase inhibitor
CN115073460B (en) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 Pyrimido [5,4-c ] [2,6] naphthyridine derivative, preparation method thereof, pharmaceutical composition and application
CN117402162A (en) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 WEE1 inhibitor and preparation and application thereof
WO2024012549A1 (en) * 2022-07-15 2024-01-18 映恩生物制药（苏州）有限公司 Pyrimido-five-membered heterocyclic compound, and preparation method therefor and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (en) 1981-08-24 1984-04-30 May & Baker Ltd New imidazotetrazionones, their preparation and medicines containing them.
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (en) * 1987-08-26 1997-07-09 三井製薬工業株式会社 Pyrimidines and their pharmaceutically acceptable salts
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0547165B1 (en) 1990-09-28 1999-11-10 Smithkline Beecham Corporation Process for the Preparation of Water-Soluble Camptothecin Analogues, as well as the compounds 10-Hydroxy-11-C(1-6)-alkoxycamptothecin
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
ATE215565T1 (en) 1992-10-28 2002-04-15 Genentech Inc USE OF ANTI-VEGF ANTIBODIES TO TREAT CANCER
JP3025602B2 (en) 1993-05-21 2000-03-27 デビオファーム エス．アー． Method for producing optically high purity cis-oxalate (trans-l-l, 2-cyclohexanediamine) platinum (II) complex
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
JP3154399B2 (en) 1996-07-04 2001-04-09 デビオファーム エス．アー． Method for producing platinum compound
CZ27399A3 (en) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
SE0103649D0 (en) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
BR0309783A (en) 2002-04-26 2005-03-22 Warner Lambert Co Control point kinase inhibitors (wee1 and chk1)
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004021558D1 (en) 2003-01-17 2009-07-30 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
US7407962B2 (en) * 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
JP4810426B2 (en) 2004-07-01 2011-11-09 第一三共株式会社 Thienopyrazole derivative having PDE7 inhibitory action
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
AR060635A1 (en) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd DERIVATIVES OF 1,2-DIHIDRO-3H-PIRAZOLO [3,4-D] PIRIMIDIN-3-ONA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
NO341617B1 (en) 2017-12-11
DE602007008085D1 (en) 2010-09-09
JPWO2007126128A1 (en) 2009-09-17
ATE475662T1 (en) 2010-08-15
CN101432284A (en) 2009-05-13
CY1118526T1 (en) 2017-07-12
EP2016080B1 (en) 2010-07-28
IL194367A0 (en) 2009-08-03
PL2016080T3 (en) 2011-03-31
KR101409161B1 (en) 2014-06-19
KR20090017491A (en) 2009-02-18
SI2016080T1 (en) 2011-03-31
US20110189130A1 (en) 2011-08-04
AU2007244185B2 (en) 2012-10-04
EP2017278A4 (en) 2009-04-22
CA2650119C (en) 2017-03-14
CA2650119A1 (en) 2007-11-08
TW200811176A (en) 2008-03-01
UA96152C2 (en) 2011-10-10
JP4513919B2 (en) 2010-07-28
EP2016080A4 (en) 2009-05-13
NZ571196A (en) 2011-03-31
HRP20100563T1 (en) 2010-11-30
US8791125B2 (en) 2014-07-29
EP2017278A1 (en) 2009-01-21
RU2437885C2 (en) 2011-12-27
PT2017278T (en) 2017-01-03
ECSP088812A (en) 2008-11-27
HRP20161763T1 (en) 2017-02-24
WO2007126128A1 (en) 2007-11-08
GT200800211A (en) 2009-04-07
TWI409262B (en) 2013-09-21
DK2016080T3 (en) 2010-11-22
MX2008013063A (en) 2008-12-16
DOP2007000084A (en) 2007-12-31
ZA200807748B (en) 2009-10-28
US7935708B2 (en) 2011-05-03
AU2007244185A1 (en) 2007-11-08
EP2017278B1 (en) 2016-11-02
ES2609087T3 (en) 2017-04-18
HK1132498A1 (en) 2010-02-26
JP2010132689A (en) 2010-06-17
SI2017278T1 (en) 2017-05-31
US20140303178A1 (en) 2014-10-09
PT2016080E (en) 2010-10-14
DK2017278T3 (en) 2017-02-13
JP5167291B2 (en) 2013-03-21
AR060635A1 (en) 2008-07-02
PE20080695A1 (en) 2008-06-28
HUE032987T2 (en) 2017-11-28
SV2009003060A (en) 2009-04-28
MA30428B1 (en) 2009-05-04
RU2008146759A (en) 2010-06-10
IL194367A (en) 2014-12-31
CN101432284B (en) 2012-08-15
MY145408A (en) 2012-02-15
WO2007126122A1 (en) 2007-11-08
CR10359A (en) 2009-02-19
PL2017278T3 (en) 2017-10-31
HN2008001532A (en) 2009-06-10
LT2017278T (en) 2017-01-25
ES2348751T3 (en) 2010-12-13
US20100063024A1 (en) 2010-03-11
US7834019B2 (en) 2010-11-16
US20070254892A1 (en) 2007-11-01
EP2016080A1 (en) 2009-01-21
BRPI0710081A2 (en) 2011-08-02
CY1111069T1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
NO20084968L (en) Dihydropyrazolpyrimidinonderivater
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
NO20083207L (en) Inhibitors of IAP
WO2004098518A3 (en) Pyrazole-amide compounds useful as kinase inhibitors
UA94424C2 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
NO20091603L (en) Chemical connections
TW200714604A (en) Substituted heterocycles and the uses thereof
TW200635918A (en) Pharmaceutical compounds
DE602004028907D1 (en) COMPOUNDS SUITABLE AS KINASEINHIBITORS ON THIAZOLYL BASIS
NO20085176L (en) Phenyl substituted heteroaryl derivatives and use as anti-tumor agents
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
NO20082482L (en) Carbonylamino pyrrole pyrazoles, as well as use as kinase inhibitors
NO20070555L (en) Quinazolinone derivatives as PARP inhibitors
TW200612947A (en) Organic compounds
UA89618C2 (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose)polymerase inhibitors
NO20074311L (en) Quinazoline derivative with tyrosine kinase inhibitory activity
MX2009003821A (en) N-aryl pyrazole compounds for use against diabetes.
MX2009004140A (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors.
ATE430743T1 (en) BENZIMIDAZOLE SUBSTITUTED THIOPHENE DERIVATIVES ACTING ON IKK3
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
NO20076145L (en) Ureadeviates, processes for their preparation and use thereof
TW200613297A (en) Pyrazole derivatives
WO2006017054A3 (en) Tricyclic-heteroaryl compounds useful as kinase inhibitors
MY140963A (en) Phenylpyridylpiperazine compounds
TW200517111A (en) Glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors